Electronic Resource
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
| العنوان: | Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). |
|---|---|
| المؤلفون: | Maharry K., Murphy F., Gollerkeri A., Christy-Bittel J., Tabernero J., Price T., Kopetz S., Grothey A., Van Cutsem E., Yaeger R., Wasan H.S., Yoshino T., Desai J., Ciardiello F., Loupakis F., S Hong Y., Steeghs N., Guren T.K., Arkenau H.-T., Garcia-Alfonso P., Chantrill L., Tebbutt N., Strickland A., Karapetis C. |
| بيانات النشر: | Blackwell Publishing Ltd Netherlands 2021-02-01 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Background: BEACONCRC is a randomized, phase 3 study which evaluated the triplet of encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) and the doublet of ENCO + CETUX vs. investigator's choice of irinotecan + CETUX or FOLFIRI + CETUX in patients (pts) with BRAFV600E metastatic colorectal cancer (mCRC) whose disease had progressed after 1-2 prior regimens in the metastatic setting. Primary endpoints were overall survival (OS) and objective response rate (ORR; by blinded central review) for triplet vs control. In a previous interim analysis, triplet and doublet improvedOS andORRversus standard of care. Here we report on an updated analysis. Method(s): Updated analysis includes 6 months of additional follow-up and response data for all randomized pts. The study is ongoing. Result(s): Patients received triplet (n = 224), doublet (n = 220), or control (n = 221). Median OS was 9.3 months (95% confidence interval [CI]:8.2, 10.8) for triplet and 5.9 months (95% CI:5.1-7.1) for control (hazard ratio [HR] (95% CI): 0.60 (0.47-0.75)). Median OS for doublet was 9.3 months (95% CI: 8.0-11.3) (HR vs control: 0.61 (0.48- 0.77). Confirmed ORR was 26.8% (95% CI: 21.1%-33.1%) for triplet, 19.5% (95% CI: 14.5%-25.4%) for doublet, and 1.8% (95% CI: 0.5%- 4.6%) for control. Retrospective subgroup analyses suggested some pts may benefit more from triplet than doublet therapy (Table). Both triplet and doublet showedimprovedOS compared to control in all subgroups. Adverse events were consistent with prior analysis, with grade >=3 adverse events in 65.8%, 57.4%, and 64.2% for triplet, doublet and control, respectively. Conclusion(s): The updated analysis of the BEACON CRC study confirmed that encorafenib + cetuximab with or without binimetinib improved OS and ORR in previously treated pts with BRAF V600E mCRC compared with standard chemotherapy. |
| مصطلحات الفهرس: | clinical trial, conference abstract, controlled study, drug therapy, female, follow up, human, major clinical study, male, metastatic colorectal cancer, overall response rate, overall survival, adult, randomized controlled trial, B Raf kinase, binimetinib, cetuximab, encorafenib, endogenous compound, irinotecan, unclassified drug, phase 3 clinical trial, cancer patient, cancer survival, chemotherapy, Conference Abstract |
| URL: | Click here for full text options LibKey Link |
| الاتاحة: | Open access content. Open access content Copyright 2021 Elsevier B.V., All rights reserved. |
| Other Numbers: | AUSHL oai:repository.monashhealth.org:1/28525 Asia-Pacific Journal of Clinical Oncology. Conference: 47th Annual Scientific Meeting, Quality and Safety, Implementation Science, Cardio-Oncology. Virtual. 16 (SUPPL 8) (pp 128), 2020. Date of Publication: November 2020. 1743-7563 https://repository.monashhealth.org/monashhealthjspui/handle/1/28525 Monash Health 634022568 (Price) Medical Oncology Unit, Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia (Kopetz) MD Anderson Cancer Center, University of Texas, Houston, TX, United States (Grothey) West Cancer Center, Germantown, TN, United States (Van Cutsem) University Hospitals Gasthuisberg Leuven, KU Leuven, Leuven, Belgium (Yaeger) Memorial Sloan Kettering Cancer Center, New York, NY, United States (Wasan) Hammersmith Hospital, Imperial College Health Care Trust, London, United Kingdom (Yoshino) National Cancer Center Hospital East, Kashiwa, Japan (Desai) PeterMacCallum Cancer Centre, Melbourne, VIC, Australia (Ciardiello) University of Campania, Naples, Italy (Loupakis) Istituto Toscano Tumori, Pisa, Italy (S Hong) Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (Steeghs) Netherlands Cancer Institute, Amsterdam, Netherlands (Guren) Department of Oncology, Oslo University Hospital, Oslo, Norway (Arkenau) Sarah Cannon Research Institute UK Limited, London, United Kingdom (Garcia-Alfonso) Hospital General Universitario Gregorio Maranon, Madrid, Spain (Chantrill) St Vincent's Hospital, Sydney, NSW, Australia (Chantrill) Illawarra Cancer Care Centre, Wollongong Hospital, Wollongong, NSW, Australia (Tebbutt) Medical Oncology, Austin Health, Melbourne, VIC, Australia (Strickland) Monash Health and Monash University, Melbourne, VIC, Australia (Karapetis) Flinders Medical Centre and Flinders University, Adelaide, SA, Australia (Murphy) Mater Hospital, Brisbane, QLD, Australia (Gollerkeri, Maharry, Christy-Bittel) Pfizer Inc., Cambridge, MA, United States (Gollerkeri, Maharry, Christy-Bittel) Pfizer Inc., Boulder, CO, United States (Tabernero) Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (Price) Medical Oncology Unit, Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia (Kopetz) MD Anderson Cancer Center, University of Texas, Houston, TX, United States (Grothey) West Cancer Center, Germantown, TN, United States (Van Cutsem) University Hospitals Gasthuisberg Leuven, KU Leuven, Leuven, Belgium (Yaeger) Memorial Sloan Kettering Cancer Center, New York, NY, United States (Wasan) Hammersmith Hospital, Imperial College Health Care Trust, London, United Kingdom (Yoshino) National Cancer Center Hospital East, Kashiwa, Japan (Desai) PeterMacCallum Cancer Centre, Melbourne, VIC, Australia (Ciardiello) University of Campania, Naples, Italy (Loupakis) Istituto Toscano Tumori, Pisa, Italy (S Hong) Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (Steeghs) Netherlands Cancer Institute, Amsterdam, Netherlands (Guren) Department of Oncology, Oslo University Hospital, Oslo, Norway (Arkenau) Sarah Cannon Research Institute UK Limited, London, United Kingdom (Garcia-Alfonso) Hospital General Universitario Gregorio Maranon, Madrid, Spain (Chantrill) St Vincent's Hospital, Sydney, NSW, Australia (Chantrill) Illawarra Cancer Care Centre, Wollongong Hospital, Wollongong, NSW, Australia (Tebbutt) Medical Oncology, Austin Health, Melbourne, VIC, Australia (Karapetis) Flinders Medical Centre and Flinders University, Adelaide, SA, Australia (Murphy) Mater Hospital, Brisbane, QLD, Australia (Gollerkeri, Maharry, Christy-Bittel) Pfizer Inc., Cambridge, MA, United States (Gollerkeri, Maharry, Christy-Bittel) Pfizer Inc., Boulder, CO, United States (Tabernero) Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (Strickland) Monash Health and Monash University, Melbourne, VIC, Australia 1305135790 |
| المصدر المساهم: | MONASH HEALTH LIBRS From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1305135790 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |